In Phase 3 trials so far, its delivered up to 28.7% body-weight loss at 68 weeks at the 12 mg dose in adults with obesity and knee osteoarthritis, alongside meaningful reductions in knee pain
Assessment of heterogeneity The evaluation of heterogeneity began with an analysis of forest plots
How does RxSpan MD handle my health data
Some BCBS insurance plans have reduced or eliminated weight loss drug coverage due to rising costs, although it may still be covered for other indications, such as cardiovascular risk reduction and liver disease (MASH)
In a rodent model, a novel GLP-1R/GIPR/GCGR triple agonist, SAR441255, has been shown to promote weight loss and the maintenance of healthy blood glucose levels and is superior to the GLP-1R/GCGR dual agonist (Bossart et al., 2022)
using it to reduce abdominal fat outside that indication is an off-label application that should be discussed directly with a prescribing provider, and like the GLP-1 drugs above, it requires a prescription rather than being sold over the counter
